ASX ANNOUNCEMENT

8 June 2022

ZENIVOL® improves Insomnia Severity Index (ISI) scores and is well tolerated in the real-world setting

ZENIVOL® LONGITUDINAL, REAL-WORLD DATA TRIAL IN INSOMNIA SUPPORTS EFFECTIVNESS IN MANAGING TREATMENT OF INSOMNIA

Key Highlights

- Results of longitudinal, real-world data (RWD) from 94 patients using ZENIVOL® supports its effectiveness as a therapeutic option to manage chronic insomnia symptoms.
- ZENIVOL® reduced the Insomnia Severity Index (ISI) scores from 19.5 *(Moderate clinical insomnia)* to 14.3 *(Subthreshold insomnia)*.
- 44% of patients on ZENIVOL® were reduced to *Subthreshold insomnia* levels and a further 22% achieved a rating of *No clinically significant insomnia*.
- An effective dosing range was established based on the results of this study.
- Completes the observational trial conducted in partnership with Emyria.
- This data will be used to support the design of future interventional clinical trials with ZENIVOL®.

Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a global leader in the research, development and commercialisation of clinically validated cannabinoid medicines, is pleased to announce that it has published a white paper detailing the analysis of longitudinal, real-world data (RWD) generated from patients using ZENIVOL®.

The agreement between Zelira Therapeutics and Emyria Ltd (ASX:EMD) was to collect longitudinal, real world data for patients diagnosed with chronic insomnia who were treated with Zelira's ZENIVOL® product including de-identified patient data relating to diagnosis and co-morbidities, concomitant medications, dosages prescribed to patients and the effectiveness of ZENIVOL® using various clinical and subjective endpoints including the Insomnia Severity Index (ISI) questionnaire.

The longitudinal, real-world data (RWD) of 94 patients was generated from two data sources:

1. Dispensing data obtained as part of Zelira's regulatory obligations and

2. Zelira sponsored observational trial conducted by Emyria's Emerald Clinics (n = 42).

The results published in a white paper are available on Zelira's website here.

A summary of the key findings include:

- Mean age of patients on ZENIVOL® was 54 years of age; the youngest and oldest patient were 6 and 78 years of age respectively.
  - A substantial proportion of active ZENIVOL® patients were over the age of 65 suggesting that in the short to medium term, ZENIVOL® is safe and effective in this cohort.
- Mean time on ZENIVOL® was 4.3 months; maximum treatment time to-date was 10.8 months.
- The primary indications of patients receiving ZENIVOL® was Chronic non-cancer pain (44%), Insomnia (36%) and post-traumatic stress disorder (12%)
- The Emerald Clinics ZENIVOL® patients, most reported being on a concomitant medication for pain relief ranging from opioids (i.e., oxycodone, codeine, tramadol), to benzodiazepines (diazepam) to over-the-counter pain relief medications (i.e., paracetamol, ibuprofen).
- ZENIVOL® appears to be effective:
  - Overall, patients had a mean baseline ISI score of 19.5 *(Moderate clinical insomnia)*, however after taking ZENIVOL® the mean ISI score significantly reduced to 14.3 (*Subthreshold insomnia* levels) ($p<0.001$).
  - At baseline, 15 patients were rated as having *Severe clinical insomnia*. After being on ZENIVOL®, 33% of these patients had reduced their ISI score to *Moderate clinical insomnia* levels, and 40% had reduced to *Subthreshold insomnia* levels. No improvement in the ISI score was seen in 27% of the *Severe clinical insomnia* patients.
  - At baseline, nine (9) patients were rated as having *Moderate clinical insomnia*. After being on ZENIVOL®, a third saw no improvement in their insomnia, whilst 44% reduced their ISI score to *Subthreshold insomnia* levels and 22% achieved ISI scores that rated them as having *No clinically significant insomnia*.
  - For those patients with *Subthreshold insomnia* at baseline, 20% were able to reduce their ISI scores to *No clinically significant insomnia*, with the remainder maintaining a *Subthreshold insomnia* rating.

Change in insomnia status whilst on ZENIVOL®, as measured by the Insomnia Severity Index (ISI)



ZENIVOL® patients in the real-world data study appeared to dose escalate over time. However the dosing remained aligned to the phase 1b/2a clinical trial. Patients typically started on 0.5mL (10mg THC: 1mg CBN: 0.5mg CBD) with a few patients increasing the doses to between 0.75mL to 1mL (20mg THC: 2mg CBN: 1mg CBD) after 3 months on treatment. Patients typically took ZENIVOL® in the evening.

Average total daily THC dose of Emerald Clinics ZENIVOL® patients



Zelira's proprietary ZENIVOL® formulation was launched in Australia in September 2020 and is available to prescribers and patients through the Therapeutic Goods Administrations (TGA) Special Access and Authorised Prescriber Schemes.

Zelira Therapeutics Managing Director & CEO, Dr Oludare Odumosu commented:

"The results of this longitudinal, real-world data study are consistent with the previously published Phase 1b/2a clinical trial. Moreover, it continues to build the story for ZENIVOL® as an effective and safe therapeutic treatment for chronic insomnia symptoms. Prescribers and patients can be confident in this clinically-validated cannabinoid medicine. These results build a strong platform to accelerate additional clinical and regulatory validations for our Rx products."

This announcement has been approved and authorised for release by the board of Zelira Therapeutics Limited.

For further information please contact

Company
Dr Oludare Odumosu
Managing Director & CEO
+1 909 855 0675
oodumosu@zeliratx.com

Investors
Ronn Bechler
Executive Chairman, Market Eye
+61 400 009 774
ronn.bechler@marketeye.com.au

About Zelira Therapeutics

Australia
Level 3, 101 St Georges Terrace
Perth WA 6000, AUSTRALIA
+61 8 6558 0886
Fax: +61 8 6316 3337
enquiries@zeliratx.com
www.zeliratx.com
ACN 103 782 378

USA
5110 Campus Drive, Suite 150
Plymouth Meeting, PA 19462
United States Of America
+1 484-630-0650

About Zelira www.zeliratx.com

Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) is a leading global biopharmaceutical company in the research, development and commercialisation of clinically-validated cannabinoid medicines. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to access the world's largest and fastest growing markets. The Company is focused on developing and clinically validating branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its Rx business, including insomnia, autism and chronic non-cancer pain.

The Company has two proprietary formulations under the HOPE® brand that are generating revenues in Australia, Pennsylvania, Louisiana and Washington D.C. with other states in the US expected to follow. Zelira is also generating revenue in Australia from its proprietary and patented Zenivol® - a leading cannabinoid-based medicine for treatment of chronic insomnia. Zenivol® has successfully completed the first Phase 1b/2a clinical trial for chronic insomnia where it was found to be a safe and effective treatment. This clinical trial is published in the prestigious journal 'Sleep'. In 2020, Zelira partnered with SprinJene®Natural to develop and commercialise natural and organic oral care products under the SprinjeneCBD brand, as part of Zelira's OTC business. The SprinjeneCBD toothpaste product is the first of several scientifically formulated, hemp-derived, oral care products containing cannabinoids and based on the proprietary and patented technology of Blackseed oil and Zinc.

The Company conducts its work in partnership with world-leading researchers and organizations which since inception includes Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in Perth; St. Vincent's Hospital in Melbourne, Australia; and the Children's Hospital of Philadelphia (CHOP) in the United States.